Company intelligence / Profile preview

Altum Pharmaceuticals Inc.

Vancouver, British Columbia, Canadabloomberg.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed a Phase 1/2 randomized, double-blind, placebo-controlled trial of inhaled Interferon α2b (AP-003) for the treatment of COVID-19. The study evaluated efficacy and safety when administered via inhalation twice daily for 10 days[6].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Interferon-based therapeuticsBiPhasix™ liposomal delivery system
Industry: Biotech

Drug pipeline

3 assets

AP-003

Pre-clinical

Indications: COVID-19

2 more assets in the full pipeline.

Request access →

Partnerships

European-based investor group

Beyond the preview

Go deeper on Altum Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altum Pharmaceuticals Inc..

Explore the full profile